Ki-67 promotes circulating tumor cell intravasation and metastasis in breast cancer

  • Cell Rep. 2026 May 26;45(5):117354. doi: 10.1016/j.celrep.2026.117354.
Yongzhan Zhang  1 Jianwen Zhou  1 Karin Strittmatter  1 Yu Wei Zhang  1 Maria Waldmeier  1 Simran Asawa  1 Marko Vujanovic  1 Selina Budinjas  1 Massimo Saini  1 Ece Su Ildiz  1 Ana Gvozdenovic  1 Werner Kovacs  1 Francesc Castro-Giner  1 Nicola Aceto  2
Affiliations
  • 1. Department of Biology, Institute of Molecular Health Sciences, Swiss Federal Institute of Technology (ETH) Zurich, Zurich, Switzerland.
  • 2. Department of Biology, Institute of Molecular Health Sciences, Swiss Federal Institute of Technology (ETH) Zurich, Zurich, Switzerland. Electronic address: [email protected].
Abstract

Ki-67, a canonical proliferation marker, represents a pivotal prognostic and predictive biomarker in breast Cancer. Here, by profiling 88,208 single-cell transcriptomes of circulating tumor cells (CTCs) matched with primary and metastatic lesions in breast Cancer mouse models, we uncover a striking enrichment of cell-cycle genes in CTCs, particularly in CTC clusters. Using in vivo CRISPR screens, we identify Ki-67 as an essential regulator of CTC intravasation, whose knockout reduces metastasis. Mechanistically, Ki-67 depletion does not curb proliferation but suppresses genes involved in maintaining cell-cell adhesion, including CD47 and KLF4, thereby linking its expression to collective invasion dynamics. Altogether, decoupling it from its role as a proliferation marker, our findings uncover an unexpected function of Ki-67 as a molecular driver of metastatic competence.

Keywords
CP: cancer; Ki-67; breast cancer; circulating tumor cells; intravasation; metastasis.
Products